A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis
Dr. Shuvro Roy and Dr. Daniel Blockmans discuss the efficacy and safety of upadacitinib as a treatment option for giant-cell arteritis. Show reference
Read the full articleYou might also wanna read
Efficacy and Safety of Low-Dose Upadacitinib Combined With Ustekinumab in the Treatment of Refractory Crohn's Disease
Conditions : Inflammatory Bowel Disease (IBD); Crohn's Disease Interventions : Drug: Upadacitinib; Drug: Ustekinumab (UST) Sponsors : Shangh
The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching
Conditions : Primary Biliary Cholangitis (PBC); Primary Sclerosing Cholangitis (PSC); Atopic Dermatitis (AD) Interventions : Drug: Upadaciti
Fast Symptom Relief in Ulcerative Colitis: Which Rx Wins?
Upadacitinib and infliximab offer rapid relief from symptoms in biologic-naive patients with moderate-to-severe ulcerative colitis. Medscape
Four JAK Inhibitors Show Positive Late-Stage Trial Results for Axial Spondyloarthritis Treatment
Data from phase 3 studies with filgotinib, gecacitinib, and ivarmacitinib and a phase 4 study of tofacitinib in early disease are reported.
mdsc.pe·25d agoLynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis
HANGZHOU, China and SHANGHAI and BOSTON, July 15, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-s
Cardiovascular Risk in Patients With Takayasu Arteritis: A Nationwide Population-Based Cohort Study
Conditions : Takayasu Arteritis; Cardiovascular Diseases Sponsors : Groupe français d'étude des Maladies Inflammatoires de loeil Completed
Comments
Sign in to join the conversation.
No comments yet. Be the first.